Orphazyme halves board of directors – chair not up for reelection
As the firm concludes operational activities following a sale of the business to Kempharm, Oprhazyme has halved its board of directors. The firm’s chair will also step down following its AGM in June.
.jpg)
by christopher due karlsson, translated by daniel pedersen
Three is the magic number after biotech firm Orphazyme has halved its board of directors, which used to count six people, the firm reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
.jpg)
Orphazyme sells entire business to US biotech company
For subscribers
